Sangamo exits ST-920 gene therapy assets in Chapter 11 sale to PTC for USD 111 million
PTCT•ST-920 assets sold to PTC
Sangamo Therapeutics completed the sale of ST-920 Fabry gene-therapy assets to PTC Therapeutics on Sept. 17, 2026.
Consideration totaled USD 111 million in cash at closing.
Trading status of Sangamo shares
Common stock remains suspended from Nasdaq trading, now quoted on OTCID Basic Market under symbol SGMOQ.
Contingent payments and liabilities
The deal includes up to USD 100 million of milestone-based contingent payments.
PTC also assumed certain specified liabilities tied to the transferred assets.
